Please ensure Javascript is enabled for purposes of website accessibility

Welcome to Regulatory Rapporteur. This site uses cookies. Read our policy.

  • Skip to main content
  • Skip to navigation
Site name
topra-logo

The Organisation for Professionals in Regulatory Affairs
Site name
Mast navigation
  • Become a member
  • Sign in
Search our site
Menu
Close menu
  • Home
  • Medical devices
    • Back to parent navigation item
    • Medical devices
    • Combination products
    • In-vitro diagnostics
    • Software
  • Pharmaceuticals
    • Back to parent navigation item
    • Pharmaceuticals
    • ATMP
    • Chemistry, manufacturing and controls
    • Clinical trials
    • Non-clinical development
    • Product information
    • Regulatory procedures
  • Veterinary
  • CPD supplements
  • Interviews
  • Meeting reports
    • Back to parent navigation item
    • Meeting reports
    • Symposium 2021
      • Back to parent navigation item
      • Symposium 2021
      • Human Medicines
      • Medical Devices/IVDs
      • Veterinary Medicines
      • Annual Lecture
    • Symposium 2022
      • Back to parent navigation item
      • Symposium 2022
      • Human Medicines
      • Medical Devices/IVDs
      • Veterinary Medicines
      • Annual Lecture
  • Editorials
  • topra-logo

    The Organisation for Professionals in Regulatory Affairs
  • Home
  • Medical devices
      • Combination products
      • In-vitro diagnostics
      • Software
    • AdobeStock_264649866
      Translating digitalisation trends into tangible solutions
    • AdobeStock_474265160
      What can past decision-making data tell us about how the FDA will make future combination product categorisation decisions?
    • AdobeStock_405906571-min
      Practical insights into the recent EU MDR framework
  • Pharmaceuticals
      • ATMP
      • Chemistry, manufacturing and controls
      • Clinical trials
      • Non-clinical development
      • Product information
      • Regulatory procedures
    • AdobeStock_393791829
      Data governance as a strategic imperative for regulatory compliance
    • AdobeStock_286032180
      Exploring Amgen’s Project Orbis experience with sotorasib (Part 2)
    • AdobeStock_244609855
      A regulatory view on the change management process for medicinal products
  • Veterinary
  • CPD supplements
  • Interviews
  • Meeting reports
      • Symposium 2021
        • Human Medicines
        • Medical Devices/IVDs
        • Veterinary Medicines
        • Annual Lecture
      • Symposium 2022
        • Human Medicines
        • Medical Devices/IVDs
        • Veterinary Medicines
        • Annual Lecture
    • 5M4A4751_TOPRA Symposium 2022_Day 3_20221019
      IVD1: Current state – and update on IVDR implementation
    • 5M4A2062_TOPRA Symposium 2022_Day 2_20221018
      VM2: Novel therapies in animal health – Balancing guidance versus gaining flexibility
    • 5M4A11193_TOPRA Symposium 2022_Day 1_20221017
      HM3: Lessons learned and strategic priorities
  • Editorials
  • More navigation items

Editorial

5M4A1970_TOPRA Symposium 2022_Day 2_20221018

Waltzing into change in Vienna: The regulatory future comes into focus

By Julie Warner, Pascale Canning

Editor's pick

  • Previous
  • Next
  • wheelchair professional

    A regulatory lens on an industry imperative: Diversity in clinical research

  • cancer therapy

    A review of Project Orbis: An initiative enabling faster patient access to cancer therapies

  • Brexit supply chain

    Brexit − Regulatory and supply chain considerations

  • AdobeStock_228931204

    Evolutions in patient healthcare at the MHRA

  • hemp

    Hype over hemp as a veterinary feed additive?

  • medicines

    Regulating medicines in a surge of change

Latest

5M4A2492_TOPRA Symposium 2022_Day 2_20221018

Access to medicines beyond Europe: The potential of reliance

By Francesca Buttigieg

5M4A5957_TOPRA Symposium 2022_Day 3_20221019

IVD3: IVDR for small companies and start-ups

By Celia Cruz

5M4A4751_TOPRA Symposium 2022_Day 3_20221019

IVD1: Current state – and update on IVDR implementation

By Esteban Herrero-Martinez

5M4A6035_TOPRA Symposium 2022_Day 3_20221019

MD5: How to maintain your medical device on the market and fulfil ongoing obligations in the post-launch phase

By Mehryar Behizad

...

Read By Issue

  • Previous
  • Next
  • RR-Cover-Dec-2022-300px

    December 2022

  • RR NOV22 Cover 300px

    November 2022

  • Screenshot 2022-09-16 102721

    October 2022

  • September 2022 cover 300px

    September 2022

  • JulyAugust 2022

    July/August 2022

  • June 22

    June 2022

  • May 22

    May 2022

  • april 22

    April 2022

  • march 22

    March 2022

  • Feb 22

    February 2022

  • jan 22

    January 2022

  • December 21

    December 2021

  • search the archive (1)

    Search the archive

  • Editorial board
  • Future features
  • Glossary
  • Privacy policy
  • Search the archive
  • TOPRA membership
  • What is regulatory affairs?

Regulatory Rapporteur

The peer-reviewed journal, published 11 times per year and available free to TOPRA members.

Follow TOPRA
topra-logo

The Organisation for Professionals in Regulatory Affairs

TOPRA office
TOPRA Publishing, 6th Floor, 3 Harbour Exchange, South Quay, London E14 9GE, UK
Tel: +44 (0) 20 7510 2560
Email: publications@topra.org

TOPRA AISBL
Blvd du Souverain 280, 1160 Brussels, Belgium Tel: +32 (0) 2 808 72 70

  • Issues
  • Contact us
  • Topics A-Z
  • Contributors A-Z
  • © 2022 Regulatory Rapporteur

Site powered by Webvision Cloud